Advisor Partners LLC grew its holdings in shares of AstraZeneca plc (NYSE:AZN) by 22.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,284 shares of the company’s stock after acquiring an additional 2,994 shares during the period. Advisor Partners LLC’s holdings in AstraZeneca were worth $644,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also modified their holdings of the company. NEXT Financial Group Inc bought a new stake in shares of AstraZeneca during the 3rd quarter valued at $169,000. Bessemer Group Inc. boosted its holdings in AstraZeneca by 64.3% in the 2nd quarter. Bessemer Group Inc. now owns 4,651 shares of the company’s stock worth $163,000 after buying an additional 1,820 shares during the period. FNY Investment Advisers LLC bought a new position in AstraZeneca in the 2nd quarter worth $175,000. Tiverton Asset Management LLC bought a new position in AstraZeneca in the 2nd quarter worth $178,000. Finally, Huntington National Bank boosted its holdings in AstraZeneca by 66.4% in the 3rd quarter. Huntington National Bank now owns 5,345 shares of the company’s stock worth $212,000 after buying an additional 2,132 shares during the period. 16.03% of the stock is owned by hedge funds and other institutional investors.
In related news, major shareholder Plc Astrazeneca acquired 600,000 shares of the company’s stock in a transaction on Monday, October 22nd. The stock was acquired at an average price of $5.00 per share, with a total value of $3,000,000.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of AstraZeneca stock opened at $41.49 on Wednesday. The firm has a market capitalization of $103.77 billion, a P/E ratio of 9.69, a PEG ratio of 2.19 and a beta of 0.57. The company has a quick ratio of 0.66, a current ratio of 0.86 and a debt-to-equity ratio of 1.36. AstraZeneca plc has a fifty-two week low of $31.99 and a fifty-two week high of $41.78.
AstraZeneca (NYSE:AZN) last released its quarterly earnings data on Thursday, November 8th. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.33 by $0.38. AstraZeneca had a net margin of 11.29% and a return on equity of 27.32%. The business had revenue of $5.34 billion during the quarter, compared to the consensus estimate of $5.26 billion. During the same quarter in the prior year, the firm earned $1.12 EPS. The business’s revenue was down 14.3% on a year-over-year basis. On average, sell-side analysts forecast that AstraZeneca plc will post 1.67 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This report was published by Week Herald and is owned by of Week Herald. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://weekherald.com/2018/11/14/advisor-partners-llc-acquires-2994-shares-of-astrazeneca-plc-azn.html.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: How to Invest in Growth Stocks
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.